Table of Contents

Publication date: September 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 9Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

In this study, we first tested the role of Peg-Dox in the killing of myeloid cell lines and of primary myeloid leukemia cells. Then, a Peg-Dox-based protocol was used to treat patients with myeloid neoplasms. The results showed that the Peg-Dox and Peg-Dox-based protocols had a similar killing ability in myeloid cell lines and in primary myeloid leukemia cells compared to that of conventional doxorubicin. The complete remission rate was 87.5% and 100% for patients with refractory/relapsed acute myeloid leukemia and myelodysplastic syndrome with excess blasts, respectively, after treatment with Peg-Dox. All patients develop...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Clinical Reports Source Type: research
Anthracyclines have been in clinical use for decades due to their anti-neoplastic effects in many cancers including breast cancer, leukaemia, lymphoma, sarcoma, lung cancer and multiple myeloma, however the effective use of these agents is limited by the danger of cardiotoxicity [1]. Incidence of cardiotoxicity in patients treated with anthracyclines varies according to cardiotoxicity definition, but has been reported as high as 26% for heart failure and 36% for left ventricular dysfunction [2,3], with the major predicting factor being anthracycline cumulative dose.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Editorial Source Type: research
Publication date: Available online 3 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shimoli V. Barot, Sarah S. Lee, Bhumika J. Patel, Jason N. ValentAbstractMonoclonal gammopathy of undetermined significance (MGUS) is an infrequent cause of type II mixed cryoglobulinemia (MC) yet these small B-cell clones can induce acute and profound end organ damage. Due to lack of explicit evaluation criteria, established standard of care and evidence-based guidelines, it continues to remain a diagnostic and therapeutic challenge. Here, we discuss our management approach to monoclonal gammopathy of renal signific...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Laura Nanni, Cinzia Pellegrini, Vittorio Stefoni, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kazutoshi Ebisawa, Yosuke Masamoto, Junji Koya, Arika Shimura, Aya Shinozaki-Ushiku, Kazuhiro Toyama, Kumi Nakazaki, Mineo KurokawaAbstractTreatment for B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, especially in relapsed or refractory case, is not established. A 35-year-old Japanese woman with this type of lymphoma relapsed after ABVD chemotherapy received salvage chemotherapies. Even after hidh-dose chemotherapy followed by autologous s...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Zuzan Cayci, Kerem Ozturk, Celalettin Ustun, Aazim K. Omer, Erhan Dincer, Zohar Sachs, Bruce A. Peterson, Michael A. LindenAbstractSarcoidosis has been shown to be associated with increased risk of development of several malignancies including lymphomas. On the other hand, “sarcoid-like reactions” in the absence of other clinical signs of sarcoidosis, have also been described in patients who had been treated with chemotherapy for a wide variety of malignancies. In this article, we report 3 cases who had PET...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsFor elderly patients newly diagnosed with MCL, rituximab-based regimen and bendamustine-based regimen as first-line treatment significantly decreased 1-year mortality rates, compared with chemotherapy alone.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Scott R. Goldsmith, Mark A. Fiala, Julie O’Neal, George Souroullas, Wael Toama, Ravi Vij, Mark A. SchroederAbstractBackgroundEZH2 is a histone methyltransferase that suppresses genes involved in cell cycle control. Overexpression of EZH2 has been associated with a poor prognosis in various malignancies. Pawlyn et al. recently reported poor outcomes in patients with multiple myeloma and overexpression of EZH2. In order to validate these findings, we analyzed EZH2 expression and outcomes among patients from the CoM...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We reported results of preclinical studies and clinical trials and discussed the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukaemia, acute and chronic myeloid leukaemia.In the next future the numerous experimental studies currently underway will allow us to define the role of the SINEs and the possibility of introducing these substances into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Treatment for B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, especially in relapsed or refractory case, is not established. A 35-year-old Japanese woman with this type of lymphoma relapsed after ABVD chemotherapy received salvage chemotherapies. Even after hidh-dose chemotherapy followed by autologous stem cell transplantation, only partial response could be achieved. Consolidative involved-field radiation therapy did not induce complete response and four months later a new lesion appeared at the skin inside the irradiated field.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Cancer & Oncology | Leukemia | Lymphoma | Myeloma